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Abstract. The article presents the application of the method for determining the quantitative parameters of 
erythropoiesis to patients with acute leukemia. The objective of the work is an investigation of erythropoiesis 
cytokinetic parameters under the normal health conditions and during the development of the acute 
lymphoblastic leukemia and the acute myeloblastic leukemia. It was found that the distribution of 
reticulocytes shifts towards an increase of immature reticulocyte fraction while the ratio between maturing 
and immature cells remains unchanged. The method presented can be used in clinical diagnostic and 
scientific research of bone marrow hematopoietic activity.
1 Introduction 
In 1982, in the framework of the USSR space programs 
and the study of USSR cosmonauts health after being in 
space, Ilyukhin et al. were improved the method for 
determining the quantitative parameters of erythropoiesis 
based on the reticulocyte number count. After comparing 
with the data of erythrocyte isotope labeling they 
confirmed the method reliability and recommended it for 
use in clinical diagnostic and scientific research in cases 
where the use of direct methods for the study of 
cytokinetic parameters is not possible [1]. 
Reticulocyte counts can provide useful information 
about bone marrow erythropoietic activity, the rate of 
reticulocyte delivery from the bone marrow into 
peripheral blood, and the rate of reticulocyte maturation. 
These parameters can be really important to studying the 
compensatory-adaptive reactions accompanying the 
development of malignant proliferation in the blood 
system such as leukemia and to the prediction of 
hemopoietic recovery in patients [2,3]. 
However, there is a probability to determine 
erroneously elevated immature reticulocyte fraction (IRF) 
in leukemic patients by automated reticulocyte analysis 
which means that hematologists should examine 
reticulocyte distribution carefully and don’t neglect the 
old methods such as using blood smears [4]. 
2 Experimental 
The work has been performed on the base of the 
Department of Biology of Belgorod State National 
Research University in Belgorod, Russia. In the 
                                                 
* Corresponding author: seliverstov.evgeniy.s@gmail.com 
experimental part of the work venous blood of patients 
with acute lymphoblastic leukemia (ALL) (41 samples), 
and patients with acute myeloblastic leukemia (AML) (18 
samples), who were undergoing medical treatment in the 
hematological department of the regional clinical hospital 
of Belgorod were used.  
The control studies were performed on the blood of 
healthy people (n = 50, 26 women and 24 men) of mature 
age (25–45 years) who underwent a clinical examination 
in the regional clinical hospital of Belgorod. Blood 
sampling was performed by venipuncture by specialized 
medical staff. Blood was collected in Vacuette K3E 
vacuum tubes containing dry EDTA K3 at a concentration 
of 2.0 mg (0.006843 mol/L) per 1 mL of blood.   
The study was approved by the local Ethical 
Committee of the Medical Institute of Belgorod State 
University and informed consent of all subjects was 
obtained according to the recommendations of the 
Helsinki Declaration (The International Response to 
Helsinki VI, The WMA’s Declaration of Helsinki on 
Ethical Principles for Medical Research Involving Human 
Subjects, as adopted by the 52nd WMA General 
Assembly, Edinburg, October 2000). 
Cytokinetic parameters of erythropoiesis were 
calculated by using the number of reticulocytes in 
unincubated and incubated blood [1]. Reticulocytes were 
stained by 0.1% solution of brilliant cresyl blue prepared 
in 0.9% NaCl solution.  
The blood smear was made of the unincubated blood 
mixed with the dye in a 1:1 ratio by volume and left at 
room temperature for 40 minutes. Also, another blood 
smear was made of the blood sample (100 μl) placed in a 
thermostat at 37° C for 4 hours and then stained by 
brilliant cresyl blue. 
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The number of erythrocytes per 1 μl of blood was 
counted by using a hemocytometer. 
By using an Axiostar plus microscope (Carl Zeiss, 
2010), the number of reticulocytes in unincubated and 
incubated for 4 hours of blood samples per 1000 
erythrocytes was counted. The calculation was carried out 
by using an oil immersion lens (magnification 100x). 
Based on the Heilmeyer [5], all groups of reticulocytes 
were counted. Group I: cells with a densely clumped 
reticulum, group II: cells with an extended network of 
loose reticulum, group III: cells with scattered granules 
with residual reticulum network, group IV: cells with 
grain as individual strands or scattered granules (Fig. 1). 
Fig. 1. Reticulocyte maturation groups (photos were taken by 
the authors). 
According to formulas, the half-life (the period for 
which half of the reticulocytes mature into the 
erythrocytes) of reticulocytes T1/2r (Fig. 2), the half-life 
(the period for which half of the erythrocytes are 
destroyed due to their senescence) of erythrocytes T1/2er 
(Fig. 3) and the value of the erythrocyte daily production 
per 1 μl of blood Рer/day (Fig. 4) were calculated:  
Fig. 2. Half-life of reticulocytes. 
Where Nr0 – the number of all reticulocytes per 1000 
erythrocytes before incubation, cells; Nr4 – the number of 
all reticulocytes per 1000 erythrocytes after 4 hours 
incubation, cells; t – incubation time (4 hours); T1/2r – the 
half-life of reticulocytes, hours. 
Fig. 3. Half-life of erythrocytes. 
Where T1/2er – the half-life of erythrocytes, days. 
Fig. 4. Value of the erythrocyte daily production per 1 μl of 
blood. 
Where Per/day – a value of the erythrocyte daily production 
per 1 μl of blood, thousands / (μl x days), Ner – the number 
of erythrocytes in 1 μl of blood, millions / μl. 
Using the modified Kolmogorov-Smirnov test the 
hypothesis about the uniform distribution of empirical 
data was tested. The significance of differences between 
control and experimental samples was determined using 
the Mann-Whitney U-test (p<0.05). All data are 
represented by the mean values with their standard errors. 
We did not have an access to the information about sex 
and age of patients with ALL and AML due to patient 
confidentiality which did not allow an adequate 
comparison in the sex and age groups. Therefore, the 
mean value for all samples was taken as a control and 
experimental data. 
3 Results and discussion 
Reticulocytes of I and II maturity groups were very rare 
and were represented by single cells in blood smears from 
healthy donor samples. The number of group III 
reticulocytes in the group of healthy donors was 3.11 ± 
0.37 cells per 1000 erythrocytes. For group IV 
reticulocytes this number was 13.60 ± 1.20 cells per 1000 
erythrocytes.  
The cytokinetic parameters of the erythropoiesis 
between men and women didn’t differ significantly under 
conditions of blood system physiological regeneration. 
In 46.1% of the blood samples of patients with ALL 
and 50% of the blood samples of patients with AML, 
reticulocytes were not detected, or they were represented 
by extremely rare single cells thus did not allow to 
calculate cytokinetic parameters in these samples.  
Between the control (healthy people) and the 
experimental (patients with ALL and AML) groups, 
significant differences in most of the values of cytokinetic 
parameters were not identified. Nevertheless, there was a 
general increase tendency in parameters, except the half-
life of erythrocytes in the group of patients with ALL, 
maturing/immature cells ratio (Nr4/Nr0), and number of 
erythrocytes per 1 μl of blood (tab. 1). 
There was an increase in the number of immature 
group I reticulocytes by 2033.3% (p<0.05), group II 
reticulocytes by 1768.7% (p<0.05) and group III 
reticulocytes by 216.7% (p<0.05) in the rest 53.9% of 
patients with ALL (Fig. 5).  
Also, there was an increase in the number of immature 
group I reticulocytes by 5933.3% (p<0.05) and group II 
reticulocytes by 1875% (p<0.05) in the rest 50% of 
patients with AML (Fig. 6). 
Also, there were two cases of ALL which we did not 
count in final results due to their significantly big 
difference in ratio between reticulocyte number before 
and after incubation compared to others (tab. 2). 
According to the literature data, the immature data, the 
immature reticulocyte fraction (IRF) may be termed as the 
red cell equivalent of the “left shift” typically associated 
with neutrophilic white cells [2]. The IRF recovery in 
patients with acute leukemia after chemotherapy showing 
bone marrow hematopoietic recovery earlier than absolute 
neutrophil count [3]. 
Thus, a favorable prognosis of hematopoietic recovery 
for patients who showed an increased number of 
immature reticulocyte fraction can be expected. 
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Table 1. Cytokinetic parameters of ALL and AML patients. 
Parameter Donors ALL AML 
Ner, millions/μl 3.75±0.08 4.07±0.27 3.70±0.55 
Nr0, cells/1000 erythrocytes 16.88±1.37 22.19±3.85 27.44±11.02 
Nr4, cells/1000 erythrocytes 9.92±0.97 14.62±3.11 16.56±5.20 
Nr4/Nr0 0.60±0.03 0.59±0.05 0.67±0.07 
T1/2r, hours 7.83±0.99 9.64±2.38 11.64±3.32 
T1/2er, days 23.86±3.51 23.81±6.36 41.13±11.84 
Рer/day, thousands/(μl x days) 202.19±20.45 237.15±35.46 236.72±127.42 
Group I reticulocytes, cells/1000 erythrocytes 0.06±0.03 1.22±0.64* 3.56±2.47* 
Group II reticulocytes, cells/1000 erythrocytes 0.16±0.07 2.83±0.92* 3.00±1.35* 
Group III reticulocytes, cells/1000 erythrocytes 3.11±0.37 6.74±1.44* 6.67±3.74 
Group IV reticulocytes, cells/1000 erythrocytes 13.60±1.20 15.04±2.18 14.22±3.98 
*p < 0.05 
Table 2. ALL data outliers. 
Parameter ALL case № 1 ALL case № 2 
Ner, millions/ μl 4.59 5.02 
Nr0, cells/1000 erythrocytes 67 68 
Nr4, cells/1000 erythrocytes 1 2 
Nr4/Nr0 0.01 0.03 
T1/2r, hours 0.66 0.79 
T1/2er, days 0.41 0.48 
Рer/day, thousands/ (μl x days) 7758.2 7247.6 
Group I reticulocytes, cells/1000 erythrocytes 14 0 
Group II reticulocytes, cells/1000 erythrocytes 7 20 
Group III reticulocytes, cells/1000 erythrocytes 11 15 
Group IV reticulocytes, cells/1000 erythrocytes 25 36 
 
Fig. 5. The number of different reticulocyte groups in ALL 
blood samples. 
Fig. 6. The number of different reticulocyte groups in AML 
blood samples. 
4 Conclusion 
It was found that about half of the cases of ALL and AML 
were characterized by ineffective erythropoiesis when 
erythroid progenitors were destroyed in the bone marrow. 
In the rest of the cases, the regulation of erythropoiesis 
was rearranged by increasing the number of groups I and 
II immature reticulocytes. About 5% of ALL cases were 
characterized by accelerated processes of immature red 
blood cell maturation, erythrocyte destruction, and 
erythrocyte daily production.  
However, the ratio between maturing cells and 
immature ones from the bone marrow remained the same 
as in the normal health conditions.  
The formulas used for erythropoiesis cytokinetic 
parameter calculations can be used in clinical diagnostic 
and scientific research of bone marrow hematopoietic 
activity. 
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